<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="50164">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01767129</url>
  </required_header>
  <id_info>
    <org_study_id>12-AVR-133</org_study_id>
    <nct_id>NCT01767129</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients</brief_title>
  <acronym>LID in PD</acronym>
  <official_title>A Phase 2a, Double-blind, Randomized, Placebo-controlled, Crossover Study to Evaluate the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avanir Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Michael J. Fox Foundation for Parkinson's Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Avanir Pharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Canada: Health Canada</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy, safety, and tolerability of AVP-923 capsules containing 45 mg
      dextromethorphan and 10 mg quinidine (AVP-923-45) compared to placebo for the treatment of
      levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Proof-of-concept phase 2a, double-blind, randomized, placebo-controlled, crossover study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Unified Dyskinesia Rating Scale (UDysRS), part 3</measure>
    <time_frame>2 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>UDysRS, part 4</measure>
    <time_frame>2 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Movement Disorder Society- Unified Parkinson's Disease Rating Scale (MDS-UPDRS), part III-motor score</measure>
    <time_frame>2 Weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bradykinesia</measure>
    <time_frame>2 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MDS-UPDRS part I, II, and IV</measure>
    <time_frame>2 Weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UDysRS part 1 and 2</measure>
    <time_frame>2 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD Motor Diary</measure>
    <time_frame>2 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Dyskinesia</condition>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>AVP-923-45</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AVP-923-45 twice daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo twice a day for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AVP-923-45</intervention_name>
    <description>One capsule twice daily for 14 days</description>
    <arm_group_label>AVP-923-45</arm_group_label>
    <other_name>dextromethorphan/quinidine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One capsule twice daily for 14 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females 30 to 80 years of age, inclusive.

          -  Diagnosis of idiopathic PD meeting the United Kingdom Parkinson's disease Society
             Brain Bank criteria.

          -  Levodopa-induced dyskinesia present greater than 25% of the day as per MDS-UPDRS.

          -  Dyskinesia of at least moderate severity as per MDS-UPDRS

          -  Amantadine and Monoamine Oxidase (MAO) inhibitors must be discontinued at least three
             weeks prior to randomization.

          -  Subjects currently receiving anti-parkinsonian medications, including all Levodopa
             preparations are eligible provided they have been on a stable dose of these
             medications for at least 1 month prior to randomization.

          -  Concomitant use of antidepressants such as selective serotonin reuptake inhibitors
             are allowed, provided the dose has been stable for at least 1 month prior to
             randomization.

        Exclusion Criteria:

          -  Subject had a prior surgery for PD except Deep Brain Stimulation (Deep Brain
             Stimulation must not have been performed within one year of screening)

          -  Hoehn and Yahr score of 5 when &quot;off&quot;.

          -  Subject with Cognitive impairment and/or history of psychiatric manifestations or
             active hallucinations.

          -  Subjects with any history of complete heart block, QTc prolongation, or torsades de
             pointes.

          -  Subjects with any family history of congenital QT interval prolongation syndrome.

          -  Subjects with history of postural syncope, or any history of unexplained syncope
             within the last 12 months.

          -  Subjects with a history of substance and/or alcohol abuse within the past 2 years.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sonal Patel</last_name>
    <phone>949-389-6791</phone>
    <email>spatel@avanir.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 15, 2014</lastchanged_date>
  <firstreceived_date>January 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>levodopa</keyword>
  <keyword>dyskinesia</keyword>
  <keyword>parkinson's disease</keyword>
  <keyword>AVP-923</keyword>
  <keyword>dextromethorphan</keyword>
  <keyword>quinidine</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dyskinesias</mesh_term>
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dextromethorphan</mesh_term>
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Quinidine</mesh_term>
    <mesh_term>Quinidine gluconate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
